Blis Technologies Limited · NZX:BLT

Blis Technologies — Merger or Acquisition (July 2021)

7 slides from Blis Technologies's merger presentation, July 2021

  1. Slide 1: Blis Technologies & Probi AB – Announcement of long term strategic partnership

    : BLIS °° Technologies first in probiotics Blis Technologies & Probi AB BLis 6 Announcement of long term strategic partnership - July 2021 (@)

  2. Slide 2: Key terms of the long term strategic partnership

    Key terms of the long term strategic partnership: • Establishment of a licence and supply agreement to drive increased revenue o Blis grants Probi the right to manufacture and sell BLIS K12™, BLIS M18™ as ingredients and finished products and the opportunity to collaborate on future products. • Stra

  3. Slide 3: Introducing Probi AB

    Introducing Probi AB One of the largest probiotic companies in the world Fully integrated company focused exclusively on Probi was founded by researchers in Lund, Sweden researching, manufacturing, and delivering probiotics in 1991. for supplements and functional food. Extensive global presence with

  4. Slide 4: Scope of collaboration – delivering significant value

    Scope of collaboration – delivering significant value Primary opportunities: Broader opportunities: Blis : • R&D – shared expertise to develop innovative probiotic solutions • Substantial revenue growth and increased market penetration • Scientific and clinical validation of probiotic health benefit

  5. Slide 5: Next steps for Blis

    Next steps for Blis Rapid implementation of the growth opportunity: • Technology transfer to enable future production of Blis probiotic strains under licence • Training of Probi sales force to support their customer engagement and selling activity Longer term collaboration opportunity: • R&D collabo

  6. Slide 6: Use of the capital funds

    Use of the capital funds Accelerate our growth priorities: • Skincare launch activity • D2C e-commerce investment: USA, CBEC, Australasia, Canada Pipeline investment: • New product development acceleration. Key late phase target - Probiotic Toothpaste • New strain development Internal capability inv

  7. Slide 7: Questions

    Questions Contacts: Brian Watson Tony Offen CEO Chairman 027 705 9133 021 463 336

Blis Technologies — Merger or Acquisition (July 2021) on 6ix